Advertisment

Revolutionizing Obesity Treatment: Regeneron's Approach to Prevent Muscle Loss

author-image
Ayanna Amadi
New Update
NULL

Revolutionizing Obesity Treatment: Regeneron's Approach to Prevent Muscle Loss

Advertisment

Obesity is a multifaceted global health challenge, and its repercussions extend beyond the aspect of excess weight. The complications associated with obesity, such as muscle wasting, are increasingly gaining attention from the scientific community. In a bid to address this issue, biotech giant Regeneron is exploring innovative obesity treatments that aim at combating muscle loss.

Advertisment

A New Approach to Obesity Treatment

Regeneron, under the leadership of their Chief Scientific Officer, George Yancopoulos, is venturing into a novel approach to fight obesity. The current obesity treatments often lead to substantial muscle loss, which is a significant concern. Regeneron aims to improve the quality of weight loss that patients experience by testing a combination approach from its pipeline. The company also envisions providing a solution for the challenges that arise post-obesity treatment. In an exciting development, Regeneron has acquired 2seventy bio’s cell therapy pipeline. This acquisition is expected to bolster the company's ability to combine their antibody capabilities with 2seventy’s cell therapy approach.

Focus on Muscle Preservation in Obesity Treatments

Advertisment

Existing obesity drugs have a common side effect: muscle loss. This problem is not just about aesthetics or physical strength; loss of muscle can lead to frailty and increased vulnerability to falls in patients. There is a growing concern among the medical community about this issue, and the industry is eagerly looking forward to the next generation of weight-loss therapies that can preserve and potentially enhance muscle during the weight loss process.

Upcoming Trials and Research

Regeneron is gearing up to commence testing a combination of its muscle-preserving drugs with semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, in 2024. The Phase II study aims to test different doses and combinations of semaglutide, trevogrumab, and garetosmab. These trials are a crucial step towards addressing the muscle loss side effect of obesity treatments.

Advertisment

Regeneron's Progress and Future Plans

Since 2022, Regeneron has shown significant progress in the obesity treatment space. The company's genetic approaches, including the use of two monoclonal antibodies, have displayed encouraging results in preserving lean mass and reducing fat mass during preclinical trials. Regeneron is also planning to conduct a phase 2 trial to validate these findings. In addition to these strategies, the company is exploring other innovative approaches in preclinical development, such as targeting the GPR75 gene.

In the Q4 2023 earnings review, Regeneron announced robust growth of their key products, Dupixent and Libtayo. The company also pre-announced sales of their Eylea franchise. The push into obesity treatments is seen as a potential growth driver for the company, and their ongoing efforts in this space are eagerly awaited by the medical and patient communities alike.

Conclusion

Obesity is a complex health challenge that requires innovative, multifaceted solutions. Regeneron's efforts to devise obesity treatments that prevent muscle loss represent a significant step forward in this direction. By integrating their antibody capabilities with novel approaches like cell therapy and genetic targeting, the company is paving the way for a new era in obesity treatment. The upcoming trials and research will provide more insights into the effectiveness of these strategies and their potential to revolutionize obesity treatment.

Advertisment
Chat with Dr. Medriva !